FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer

https://www.news-medical.net/news/20240805/FDA-accepted-PD-L1-inhibitor-durvalumab-for-the-treatment-of-endometrial-cancer.aspx On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency. Endometrial cancer is the most prevalent gynecologic cancer, with an estimated 66,200 new U.S. cases in 2023. This approval demonstrates the effectiveness of immune checkpoint inhibitors, particularly targeting PD-L1 (CD274, B7-H1), a crucial factor in tumor immune evasion. Studying PD-L1 is essential for developing therapies that enhance immune responses to various cancers, potentially improving treatment success and patient outcomes.